Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study)

Published on Feb 1, 2021in Thrombosis and Haemostasis4.379
· DOI :10.1055/S-0040-1714739
Nils Picker2
Estimated H-index: 2
Agnes Y.Y. Lee55
Estimated H-index: 55
(UBC: University of British Columbia)
+ 8 AuthorsThomas Wilke18
Estimated H-index: 18
Introduction Clinical guidelines recommend anticoagulation therapy for the treatment of cancer-associated venous thromboembolism (VTE), but little is known about preferences. Therefore, the objective of this discrete choice experiment (DCE) was to elucidate patient preferences regarding anticoagulation convenience attributes. Methods Adult patients with cancer-associated VTE who switched to direct oral anticoagulants were included in a single-arm study (COSIMO). Patients were asked to decide between hypothetical treatment options based on a combination of the following attributes: route of administration (injection/tablet), frequency of intake (once/twice daily), need for regular controls of the international normalized ratio (INR) at least every 3 to 4 weeks (yes/no), interactions with food/alcohol (yes/no), and distance to treating physician (1 vs. 20 km) as an additional neutral attribute. DCE data were collected by structured telephone interviews and analyzed based on a conditional logit regression. Results Overall, 163 patients (mean age 63.7 years, 49.1% female) were included. They strongly preferred oral administration compared with self-injections (importance of this attribute for overall treatment decisions: 73.8%), and a treatment without dietary restrictions (11.8%). Even if these attributes were less important (7.2% and 6.5%, respectively), patients indicated a preference for a shorter distance to the treating physician and once-daily dosing compared with twice-daily intake. “Need for regular controls of INR at least every 3 to 4 weeks” showed no significant impact on the treatment decision (0.7%). Conclusion This study showed that treatment-related decision making in cancer-associated VTE, assuming comparable effectiveness and safety of anticoagulant treatments, is predominantly driven by “route of administration,” with patients strongly preferring oral administration.
Abstract Background Recent guidelines recommend consideration of the use of oral edoxaban or rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However, the benefit of...
202 CitationsSource
#1Ann Hutchinson (University of Hull)H-Index: 6
#2Sophie Rees (Warw.: University of Warwick)H-Index: 7
Last. Miriam J. Johnson (University of Hull)H-Index: 34
view all 6 authors...
Background:Cancer patients have a four- to fivefold greater risk of thrombosis than the general population. Recommended treatment for cancer-associated thrombosis is 3–6 months of low-molecular-weight heparin. The ‘select-d’ trial is an open-label, randomised, multi-centre pilot trial in patients with cancer-associated thrombosis, utilising dalteparin (low-molecular-weight heparin) versus rivaroxaban (a direct oral anticoagulant), to assess effectiveness and safety.Aim:To explore patient and inf...
19 CitationsSource
#1Alexander T. Cohen ('KCL': King's College London)H-Index: 41
#1Alexander T. Cohen ('KCL': King's College London)H-Index: 59
Last. Miriam Bach (Bayer)H-Index: 5
view all 6 authors...
Around 20% of venous thromboembolism (VTE) cases occur in patients with cancer. Current guidelines recommend low molecular weight heparin (LMWH) as the preferred anticoagulant for VTE treatment. However, some guidelines state that vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) are acceptable alternatives for long-term therapy in some patients if LMWHs are not available. LMWHs and VKAs have a number of drawbacks that can increase the burden on patients. DOACs, such as rivarox...
13 CitationsSource
#1Annie M. Young (Warw.: University of Warwick)H-Index: 25
#2Andrea Marshall (Coventry Health Care)H-Index: 35
Last. Mark LevineH-Index: 134
view all 18 authors...
PurposeVenous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was to assess if an oral factor Xa inhibitor, rivaroxaban, would offer an alternative treatment for VTE in patients with cancer.Patient and MethodsIn this multicenter, randomized, open-label, pilot trial in the United Kingdom, patients with active cancer who had symptomatic pulmonary embolism (PE)...
509 CitationsSource
#1Gary E. RaskobH-Index: 89
#2Nick van EsH-Index: 23
Last. Harry R. BüllerH-Index: 113
view all 19 authors...
Abstract Background Low-molecular-weight heparin is the standard treatment for cancer-associated venous thromboembolism. The role of treatment with direct oral anticoagulant agents is unclear. Methods In this open-label, noninferiority trial, we randomly assigned patients with cancer who had acute symptomatic or incidental venous thromboembolism to receive either low-molecular-weight heparin for at least 5 days followed by oral edoxaban at a dose of 60 mg once daily (edoxaban group) or subcutane...
685 CitationsSource
#1A. Brett Hauber (RTP: Research Triangle Park)H-Index: 26
#2Juan Marcos Gonzalez (RTP: Research Triangle Park)H-Index: 14
Last. John F.P. Bridges (Johns Hopkins University)H-Index: 34
view all 8 authors...
Conjoint analysis is a stated-preference survey method that can be used to elicit responses that reveal preferences, priorities, and the relative importance of individual features associated with health care interventions or services. Conjoint analysis methods, particularly discrete choice experiments (DCEs), have been increasingly used to quantify preferences of patients, caregivers, physicians, and other stakeholders. Recent consensus-based guidance on good research practices, including two re...
382 CitationsSource
#1Simon Noble (Cardiff University)H-Index: 26
#2Axel MatzdorffH-Index: 1
Last. Giovanni PisaH-Index: 1
view all 5 authors...
Low molecular weight heparins have demonstrated superiority over coumarins in the extended treatment of cancer-associated thrombosis and are recommended as first-line therapy in clinical guidelines. Non-vitamin K oral antagonists are yet to be evaluated against low molecular weight heparin for this indication. Nevertheless, a perception that patients favor oral anticoagulants over injections may lead to an increased prescribing of warfarin or non-vitamin K oral antagonists despite the evidence g...
62 CitationsSource
Since the introduction of new oral anticoagulants (NOACs), besides vitamin-K antagonists, an additional option for stroke prevention of patients with atrial fibrillation (AF) is available. The objective of this study was to assess AF patients’ preferences with regard to the attributes of these different treatment options. We conducted a multicenter study among randomly selected physicians. Preferences were assessed by computer-assisted telephone interviews. We used a discrete-choice-experiment (...
31 CitationsSource
#1Esther W. de Bekker-Grob (EUR: Erasmus University Rotterdam)H-Index: 24
#2Bas Donkers (EUR: Erasmus University Rotterdam)H-Index: 28
Last. Elly A. Stolk (EUR: Erasmus University Rotterdam)H-Index: 34
view all 4 authors...
Discrete-choice experiments (DCEs) have become a commonly used instrument in health economics and patient-preference analysis, addressing a wide range of policy questions. An important question when setting up a DCE is the size of the sample needed to answer the research question of interest. Although theory exists as to the calculation of sample size requirements for stated choice data, it does not address the issue of minimum sample size requirements in terms of the statistical power of hypoth...
243 CitationsSource
#1Martin H. Prins (Maastricht University Medical Centre)H-Index: 112
#2Luke Bamber (Bayer AG: Bayer HealthCare Pharmaceuticals)H-Index: 9
Last. Anthonie W. A. Lensing (Bayer AG: Bayer HealthCare Pharmaceuticals)H-Index: 45
view all 7 authors...
Abstract Introduction Rivaroxaban is an oral, direct Factor Xa inhibitor, approved for the treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT) and the secondary prevention of recurrent PE and DVT as a fixed-dose, monotherapy regimen that does not require initial heparinisation, routine coagulation monitoring or dose adjustment. Approval in this indication was supported by results from EINSTEIN PE, a large, randomised, open-label study that compared rivaroxaban with enoxaparin/vit...
56 CitationsSource
Cited By1
#1Behnood Bikdeli (Yale University)H-Index: 22
#2David Jiménez (University of Alcalá)H-Index: 18